Back to Search
HAYLEY MURRAY, PHARMD RPH
PHARMD RPH
Pharmacist
NPI: 1013687623Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
RP456165(PA)
Research & Publications (20)
Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.
PMID 18573898·Infect Immun·2008
4-observational
Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.
PMID 16790814·Infect Immun·2006
7-preclinical
Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.
PMID 16760512·Am J Trop Med Hyg·2006
4-observational
Visceral Leishmania donovani infection in interleukin-13-/- mice.
PMID 16552085·Infect Immun·2006
7-preclinical
Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.
PMID 15972476·Infect Immun·2005
7-preclinical
Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis.
PMID 15814719·J Immunol·2005
7-preclinical
Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
PMID 15716043·Acta Trop·2005
7-preclinical
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
PMID 15482193·Expert Rev Anti Infect Ther·2004
6-review
Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.
PMID 14573667·Infect Immun·2003
7-preclinical
Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.
PMID 12878513·Antimicrob Agents Chemother·2003
7-preclinical
Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
PMID 12870129·J Infect Dis·2003
7-preclinical
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
PMID 12379707·Infect Immun·2002
7-preclinical
Tissue granuloma structure-function in experimental visceral leishmaniasis.
PMID 11703536·Int J Exp Pathol·2001
6-review
Clinical and experimental advances in treatment of visceral leishmaniasis.
PMID 11451673·Antimicrob Agents Chemother·2001
6-review
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
PMID 11179920·Int J Infect Dis·2000
6-review
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
PMID 11036063·Antimicrob Agents Chemother·2000
7-preclinical
Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.
PMID 11035738·Infect Immun·2000
7-preclinical
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
PMID 11035737·Infect Immun·2000
7-preclinical
Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
PMID 11023473·J Infect Dis·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3300 E MARKET ST
YORK, PA 17402 - Phone
- (203) 988-4643
Quick Facts
- NPI
- 1013687623
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile